Ultragenyx Receives FDA Agreement to Expand Ongoing Global Phase 1/2 Trial Evaluating GTX-102 in Patients with Angelman Syndrome in the U.S.
17 mai 2023 08h00 HE
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., May 17, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that the U.S. Food and Drug Administration (FDA) has reviewed and agreed to a protocol...
Ultragenyx Announces Upcoming Data Presentations at American Society of Gene & Cell Therapy (ASGCT) 2023 Annual Meeting
08 mai 2023 16h02 HE
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for...
Ultragenyx to Present at Bank of America’s 2023 Health Care Conference
05 mai 2023 16h01 HE
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., May 05, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
Ultragenyx Reports First Quarter 2023 Financial Results and Corporate Update
04 mai 2023 16h01 HE
|
Ultragenyx Pharmaceutical Inc.
First quarter 2023 total revenue of $100.5 million, Crysvita® revenue of $76.0 million and Dojolvi® revenue of $14.3 million Total revenue grew 26% and Crysvita revenue grew 28% versus the first...
Dennis Huang of Ultragenyx Named to MassBio’s Board of Directors
28 avr. 2023 12h27 HE
|
Ultragenyx Pharmaceutical Inc.
BEDFORD, Mass., April 28, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and...
Ultragenyx to Host Conference Call for First Quarter 2023 Financial Results and Corporate Update
27 avr. 2023 16h05 HE
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., April 27, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for...
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
19 avr. 2023 16h01 HE
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., April 19, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
Ultragenyx to Present at Guggenheim’s Genomic Medicines and Rare Disease Days
28 mars 2023 16h01 HE
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., March 28, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
21 mars 2023 08h30 HE
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., March 21, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
Ultragenyx Appoints Dr. Eric Crombez Chief Medical Officer and Executive Vice President
14 mars 2023 08h30 HE
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) announced that Eric Crombez, M.D., has been promoted to chief medical officer and executive vice...